DK169120B1 - Anvendelse af L-tryptophan og en perifer nedbrydningshæmmer for L-tryptophan til fremstilling af et smertestillende middel - Google Patents

Anvendelse af L-tryptophan og en perifer nedbrydningshæmmer for L-tryptophan til fremstilling af et smertestillende middel Download PDF

Info

Publication number: DK169120B1
Authority: DK; Denmark
Prior art keywords: tryptophan; pain; peripheral; inhibitor; use according
Prior art date: 1986-12-13

Application number

DK452788A

Other languages

Danish (da)

English (en)

Other versions

DK452788A (da

DK452788D0 (da

Inventor

Joachim Kamprad

Ludger Rolf

Original Assignee

Joachim Kamprad

Ludger Rolf

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-12-13

Filing date

1988-08-12

Publication date

1994-08-22

1988-08-12 Application filed by Joachim Kamprad, Ludger Rolf filed Critical Joachim Kamprad

1988-08-12 Publication of DK452788A publication Critical patent/DK452788A/da

1988-08-12 Publication of DK452788D0 publication Critical patent/DK452788D0/da

1994-08-22 Application granted granted Critical

1994-08-22 Publication of DK169120B1 publication Critical patent/DK169120B1/da

Links

QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title claims abstract description 85
229960004799 tryptophan Drugs 0.000 title claims abstract description 47
239000003112 inhibitor Substances 0.000 title claims abstract description 20
230000002093 peripheral effect Effects 0.000 title claims abstract description 20
230000015556 catabolic process Effects 0.000 title claims abstract description 19
230000000202 analgesic effect Effects 0.000 title description 6
238000006731 degradation reaction Methods 0.000 claims abstract description 16
238000002360 preparation method Methods 0.000 claims abstract description 8
208000002193 Pain Diseases 0.000 claims description 34
230000036407 pain Effects 0.000 claims description 26
239000000203 mixture Substances 0.000 claims description 20
239000002775 capsule Substances 0.000 claims description 13
239000003954 decarboxylase inhibitor Substances 0.000 claims description 9
230000003111 delayed effect Effects 0.000 claims description 9
239000013543 active substance Substances 0.000 claims description 8
239000000416 hydrocolloid Substances 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 3
239000012530 fluid Substances 0.000 claims description 3
-1 2,3,4-trihydroxybenzyl Chemical group 0.000 claims description 2
OFKWWALNMPEOSZ-UHFFFAOYSA-N 3-(hydrazinylmethyl)phenol Chemical compound NNCC1=CC=CC(O)=C1 OFKWWALNMPEOSZ-UHFFFAOYSA-N 0.000 claims description 2
108010031676 Kynureninase Proteins 0.000 claims description 2
CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical group OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 claims description 2
102000005447 kynureninase Human genes 0.000 claims description 2
210000002784 stomach Anatomy 0.000 claims description 2
239000007787 solid Substances 0.000 claims 2
230000002496 gastric effect Effects 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
229940035676 analgesics Drugs 0.000 abstract description 2
239000000730 antalgic agent Substances 0.000 abstract description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 44
229940076279 serotonin Drugs 0.000 description 19
230000000694 effects Effects 0.000 description 16
BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 15
229960000911 benserazide Drugs 0.000 description 14
239000003814 drug Substances 0.000 description 7
238000012360 testing method Methods 0.000 description 7
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 6
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 6
239000008280 blood Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
229940079593 drug Drugs 0.000 description 6
208000000094 Chronic Pain Diseases 0.000 description 5
208000000114 Pain Threshold Diseases 0.000 description 5
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
239000002858 neurotransmitter agent Substances 0.000 description 5
230000037040 pain threshold Effects 0.000 description 5
239000002243 precursor Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
241000282414 Homo sapiens Species 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
230000008499 blood brain barrier function Effects 0.000 description 4
210000001218 blood-brain barrier Anatomy 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
239000008187 granular material Substances 0.000 description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
238000000034 method Methods 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
230000002295 serotoninergic effect Effects 0.000 description 4
102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 3
108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229960004205 carbidopa Drugs 0.000 description 3
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
230000003902 lesion Effects 0.000 description 3
239000005445 natural material Substances 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
230000008569 process Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
229940123736 Decarboxylase inhibitor Drugs 0.000 description 2
208000020401 Depressive disease Diseases 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
208000003443 Unconsciousness Diseases 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 2
235000010216 calcium carbonate Nutrition 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
230000006652 catabolic pathway Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000011436 cob Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
229960003638 dopamine Drugs 0.000 description 2
206010013663 drug dependence Diseases 0.000 description 2
230000002996 emotional effect Effects 0.000 description 2
239000001530 fumaric acid Substances 0.000 description 2
238000000227 grinding Methods 0.000 description 2
239000010514 hydrogenated cottonseed oil Substances 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 2
210000003715 limbic system Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229910000150 monocalcium phosphate Inorganic materials 0.000 description 2
235000019691 monocalcium phosphate Nutrition 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
229940127240 opiate Drugs 0.000 description 2
229960002888 oxitriptan Drugs 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 1
LDCYZAJDBXYCGN-UHFFFAOYSA-N 5-hydroxytryptophan Chemical compound C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
208000009079 Bronchial Spasm Diseases 0.000 description 1
208000014181 Bronchial disease Diseases 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
208000001294 Nociceptive Pain Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000004983 Phantom Limb Diseases 0.000 description 1
206010056238 Phantom pain Diseases 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
208000019902 chronic diarrheal disease Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000022371 chronic pain syndrome Diseases 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000003001 depressive effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
229940120889 dipyrone Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000008451 emotion Effects 0.000 description 1
201000003104 endogenous depression Diseases 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000012041 food component Nutrition 0.000 description 1
239000005417 food ingredient Substances 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
208000024714 major depressive disease Diseases 0.000 description 1
LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
230000008693 nausea Effects 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000037325 pain tolerance Effects 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000009993 protective function Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000021317 sensory perception Effects 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000001519 thymoleptic effect Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Indole Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK452788A 1986-12-13 1988-08-12 Anvendelse af L-tryptophan og en perifer nedbrydningshæmmer for L-tryptophan til fremstilling af et smertestillende middel DK169120B1 (da)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DE19863642668 DE3642668A1 (de)	1986-12-13	1986-12-13	Schmerzmittel fuer menschen
DE3642668		1986-12-13
PCT/EP1987/000769 WO1988004170A1 (en)	1986-12-13	1987-12-10	Pain-killer
EP8700769		1987-12-10
CA589972		1989-02-02

Publications (3)

Publication Number	Publication Date
DK452788A DK452788A (da)	1988-08-12
DK452788D0 DK452788D0 (da)	1988-08-12
DK169120B1 true DK169120B1 (da)	1994-08-22

Family

ID=6316147

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK452788A DK169120B1 (da)	1986-12-13	1988-08-12	Anvendelse af L-tryptophan og en perifer nedbrydningshæmmer for L-tryptophan til fremstilling af et smertestillende middel

Country Status (11)

Country	Link
US (1)	US5216019A (no)
EP (1)	EP0344158B1 (no)
JP (1)	JPH0645539B2 (no)
KR (1)	KR960011235B1 (no)
AT (1)	ATE74505T1 (no)
AU (1)	AU634149B2 (no)
CA (1)	CA1320133C (no)
DE (2)	DE3642668A1 (no)
DK (1)	DK169120B1 (no)
NO (1)	NO882724L (no)
WO (1)	WO1988004170A1 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102004039196B4 (de) *	2004-08-12	2008-07-31	Dr.Kamprad Kg	Neue Formulierung für L-Tryptophan
US9173860B2 (en)	2009-11-04	2015-11-03	Susan Park Perrine	S isomers of α-methyl hydrocinnamic acid for the treatment of blood disorders
DE102022103658A1 (de)	2022-02-16	2023-08-17	Joachim Kamprad	Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4126672A (en) *	1976-02-04	1978-11-21	Hoffmann-La Roche Inc.	Sustained release pharmaceutical capsules
US4167558A (en) *	1976-02-13	1979-09-11	Hoffmann-La Roche Inc.	Novel sustained release tablet formulations
US4140755A (en) *	1976-02-13	1979-02-20	Hoffmann-La Roche Inc.	Sustained release tablet formulations
EP0004040B1 (en) *	1978-03-03	1983-10-05	MERCK PATENT GmbH	Pharmaceutical compositions having analgesic properties comprising a compound selected from d- and dl-phenylalanine, d- and dl-leucine and hydrocinnamic acid in the unit dose of at least 200mg
JPS57160227A (en) *	1981-03-30	1982-10-02	Fujitsu Ltd	Frequency synthesizer
CH652025A5 (de) *	1981-09-14	1985-10-31	Hoffmann La Roche	Pharmazeutisches praeparat.
GB2113545A (en) *	1982-01-22	1983-08-10	Mayron International Inc	Treatment of migraine
GB2113546A (en) *	1982-01-22	1983-08-10	Mayron International Inc	Treatment of migraine
US4639465A (en) *	1985-08-30	1987-01-27	Commonwealth Medical Corporation Of America	Method and composition for relieving pain

1986
- 1986-12-13 DE DE19863642668 patent/DE3642668A1/de not_active Withdrawn
1987
- 1987-12-10 DE DE88900071T patent/DE3778165D1/de not_active Expired - Lifetime
- 1987-12-10 AU AU10428/88A patent/AU634149B2/en not_active Ceased
- 1987-12-10 WO PCT/EP1987/000769 patent/WO1988004170A1/de active IP Right Grant
- 1987-12-10 JP JP63500381A patent/JPH0645539B2/ja not_active Expired - Fee Related
- 1987-12-10 EP EP88900071A patent/EP0344158B1/de not_active Expired - Lifetime
- 1987-12-10 AT AT88900071T patent/ATE74505T1/de not_active IP Right Cessation
- 1987-12-10 KR KR1019880700963A patent/KR960011235B1/ko not_active IP Right Cessation
1988
- 1988-06-21 NO NO882724A patent/NO882724L/no unknown
- 1988-08-12 DK DK452788A patent/DK169120B1/da not_active IP Right Cessation
1989
- 1989-02-02 CA CA000589972A patent/CA1320133C/en not_active Expired - Fee Related
1992
- 1992-04-01 US US07/865,822 patent/US5216019A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0344158B1 (de)	1992-04-08
NO882724L (no)	1988-10-10
KR960011235B1 (ko)	1996-08-21
AU1042888A (en)	1988-06-30
DE3642668A1 (de)	1988-06-23
US5216019A (en)	1993-06-01
WO1988004170A1 (en)	1988-06-16
KR890700025A (ko)	1989-03-02
CA1320133C (en)	1993-07-13
NO882724D0 (no)	1988-06-21
AU634149B2 (en)	1993-02-18
DK452788A (da)	1988-08-12
DE3778165D1 (no)	1992-05-14
ATE74505T1 (de)	1992-04-15
DK452788D0 (da)	1988-08-12
EP0344158A1 (de)	1989-12-06
JPH02500746A (ja)	1990-03-15
JPH0645539B2 (ja)	1994-06-15

Publication	Publication Date	Title
Vijayakumar et al.	2016	Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia
RU2140266C1 (ru)	1999-10-27	Фармацевтическая композиция с регулируемым выделением на основе одной или нескольких фармацевтически приемлемых солей гамма-гидроксимасляной кислоты и способ ее получения
JP4365107B2 (ja)	2009-11-18	医薬組成物
RU2670272C2 (ru)	2018-10-22	Пероральная фармацевтическая композиция, подходящая для повышения эффективности лечения двигательных нарушений
US20230078925A1 (en)	2023-03-16	Pulsatile drug delivery system for treating morning akinesia
KR20030097892A (ko)	2003-12-31	의약 배합제
KR20050083827A (ko)	2005-08-26	서방성 ｌ-아르기닌 포뮬레이션 및 이의 제조방법 및 용도
LT3119B (en)	1994-12-27	Pharmaceutical composition and process for the preparation thereof
NZ506020A (en)	2002-05-31	Use of pharmaceutical combinations containing tramadol and an antiemetic
US10675269B2 (en)	2020-06-09	Compositions comprising melatonin
DK169120B1 (da)	1994-08-22	Anvendelse af L-tryptophan og en perifer nedbrydningshæmmer for L-tryptophan til fremstilling af et smertestillende middel
US6008222A (en)	1999-12-28	Method for oral administration of buspirone and nefazodone
NO20001717L (no)	2000-04-03	Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
KR20130119450A (ko)	2013-10-31	시트르산염 및 중탄산염을 포함하는 제약 조성물 및 시스틴뇨증을 치료하기 위한 그것의 용도
CN101022795B (zh)	2012-02-15	L-色氨酸与卡比多巴/苄丝肼的制剂
JP2022549833A (ja)	2022-11-29	経口速放出性医薬組成物および減量治療の方法
Weiner et al.	1979	Dopaminergic antagonism of L‐5‐hydroxytryptophan‐induced myoclonic jumping behavior
CN106177962B (zh)	2019-04-30	含沙格雷酯的药物组合物用于治疗或预防脂肪肝、肝纤维化和/或肝损伤的用途
CN114557992B (zh)	2024-02-27	一种复方药物组合物在制备治疗间质性肺炎药物中的应用
RU2543637C2 (ru)	2015-03-10	Пролонгированная фармацевтическая композиция гипотензивного действия и способ ее изготовления
CN112915083A (zh)	2021-06-08	药物组合物、成套药盒及其应用
US5182285A (en)	1993-01-26	Cell-protective composition for preventing or treating of peptic ulcer
Fitzpatrick	2006	Melatonin in health and disease
MD3996699T2 (ro)	2023-11-30	Combinație de ibuprofen și tramadol pentru calmarea durerii
BR112021007839A2 (pt)	2021-08-03	tratamento e prevenção de ejaculação prematura (ep)

Legal Events

Date	Code	Title	Description
1994-08-22	B1	Patent granted (law 1993)
2005-08-22	PBP	Patent lapsed	Country of ref document: DK